Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033586 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
A Phase 3 study of Polycythemia Vera, sponsored by Protagonist Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06033586 is a Phase 3 study of Polycythemia Vera that is active but no longer recruiting, run by Protagonist Therapeutics. The registered enrollment target is 46 participants, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06033586, a Phase 3 study of Polycythemia Vera, is active but no longer recruiting, sponsored by Protagonist Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.
Conditions Studied
Interventions
- DRUG Open-label rusfertide
Study Locations (1)
Louisiana
- Pontchartrain Cancer Care - Covington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06033586
The ClinicalTrials.gov registry entry for NCT06033586 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 338-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (86% lower). The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which Open-label rusfertide is the first listed.
NCT06033586 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT06033586 about?
NCT06033586 is a clinical study titled "Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera". The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligi...
What is the current status of trial NCT06033586?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2024-01-22. Estimated completion is 2027-04-01.
What conditions does trial NCT06033586 study?
This clinical trial studies the following conditions: Polycythemia Vera.
What interventions are being tested in trial NCT06033586?
The interventions under investigation include: Open-label rusfertide (DRUG).
Who is sponsoring clinical trial NCT06033586?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033586 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
RECRUITING · Phase 3
-
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.